Autoantibodies to cardiac troponin in acute coronary syndromes
2010 (English)In: Clinica Chimica Acta, ISSN 0009-8981, E-ISSN 1873-3492, Vol. 411, no 21-22, 1793-1798 p.Article in journal (Refereed) Published
Backgrounds In a recent small study, patients with autoantibodies to cardiac troponin (cTnaAb) had higher cardiac troponin 1 (cTnl) release during an episode of acute coronary syndrome (ACS) than patients without cTnaAb and continued to have higher long-term levels of cTnl However, the prognostic importance of the occurrence of cTnaAb is unknown Methods In 957 nonST-elevation ACS patients cTnaAb and cTnl were analyzed at randomization and after 6 months. Outcomes were assessed through 5 years Results. Seven and 11% of the patients were cTnaAb positive at inclusion and 6 months, respectively The cardiac troponin I (cTnl) concentration at inclusion was independently associated with the development of cTnaAb (OR 1 53, 95% Cl 1 25-1 88) The presence of cTnaAb was associated with an increased cTnl level at 6 months (OR 2 39, 95% CI 1 50-381) cTnaAb was not independently associated with death and AMI during follow-up (HR 0 97. 95% Cl 0.61-1 54) Conclusion Development of cTnaAb after an episode of nonST-elevation ACS is associated with the acute myocardial damage, but occurs only in a minority of patients Furthermore, the presence of cTnaAb is associated with chronically elevated cTnl concentrations However, the occurrence of cTnaAb is not associated with an adverse long-term prognosis.
Place, publisher, year, edition, pages
2010. Vol. 411, no 21-22, 1793-1798 p.
Myocardial infarction, Troponin l, Antibodies, Diagnosis, Prognosis
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-133745DOI: 10.1016/j.cca.2010.08.005ISI: 000282562200042OAI: oai:DiVA.org:uu-133745DiVA: diva2:370479